TransCode Therapeutics
RNAZ | NASDAQ
$1.35
+$0.03 (+2.27%)
At close: Nov 16, 2026, 4:00 PM ET
$1.37
+$0.02 (+1.48%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+2.27%
(1D)No price chart data available for 1D timeframe.
Rating
35.5
+5.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #634/1021 (Top 62%)
Key Statistics
Market Data
Market Cap $1.43M
1D Range
1.29 1.47
52W Range
1.29 12.34
Valuation (TTM)
PE -0.03
PB 0.01
EV/EBITDA 0.15
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -1582.4%
SBC Adj. FCF Yield 5115.3%
SBC Impact -423.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 120.2% |
65.2%
FCF 3Y | 5Y -20.5% |
-9.8%
Returns
ROA -28.3%
ROE -58.1%
ROIC -23.7%
Financial Health
Net Cash
$7.73M
Current Ratio 1.97
Interest Coverage -5,337.75
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease....
Sector Healthcare
Industry Biotechnology
Employees 12
IPO Date Jul 8, 2021
Website www.transcodetherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove RNAZ